Risk Factors for Chemotherapy-Induced Peripheral Neuropathy Caused by Nanoparticle Albumin-Bound Paclitaxel in Advanced Breast Cancer
Breast cancer (BC) is one of the most common malignancies affecting women and the leading cause of related mortality worldwide. An estimated 2260000 new cases of BC were diagnosed in 2020, which have seriously threatened the health. Paclitaxel (PTX), a natural product isolated from the bark of the p...
Gespeichert in:
| Veröffentlicht in: | BioMed research international 2022-09, Vol.2022, p.1-7 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 7 |
|---|---|
| container_issue | |
| container_start_page | 1 |
| container_title | BioMed research international |
| container_volume | 2022 |
| creator | Guo, Qie Zhang, Haonan Li, Xiao Quan, Xianghua |
| description | Breast cancer (BC) is one of the most common malignancies affecting women and the leading cause of related mortality worldwide. An estimated 2260000 new cases of BC were diagnosed in 2020, which have seriously threatened the health. Paclitaxel (PTX), a natural product isolated from the bark of the pacific yew, has been found to be effective in treating advanced BC. Chemotherapy-induced peripheral neuropathy (CIPN), which refers to the damage to the peripheral nerves caused by exposure to a neurotoxic chemotherapeutic agent, is a common side effect affecting the patients undergoing PTX chemotherapy. Significant research efforts are needed to identify the various risk factors associated with CIPN. Here, a univariate analysis in BC patients with nanonab-PTX treatment was performed. The rate of CIPN in BC patients with albumin-bound paclitaxel (nab-PTX) for more than four weeks was significantly higher than that of patients with chemotherapy for less than four weeks. Moreover, the rate of CIPN in BC patients receiving nab-PTX first-line chemotherapy was remarkably higher than that in BC patients receiving paclitaxel as a sequence scheme. Taken together, chemotherapy cycles and the priority of nab-PTX-based chemotherapy can be considered the potential risk factors for CIPN induced by nab-PTX. |
| doi_str_mv | 10.1155/2022/9430952 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9489370</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2717516438</sourcerecordid><originalsourceid>FETCH-LOGICAL-c425t-ac396be4edcb282c70f4da721291c850a7b69824cea4290faf2bd571d99266bd3</originalsourceid><addsrcrecordid>eNp9kc1q3DAQgE1JoSHNLQ8g6KWQupFk-UeXwmZJ2kBIS0nPYizJtVJbcvSTZB-g711tdwm0h-giaeabjxmmKE4I_khIXZ9RTOkZZxXmNX1VHNKKsLIhjBw8v6vqTXEcwh3OpyMN5s1h8fu7Cb_QJcjofECD82g96tnFUXtYNuWVVUlqhb5pb5ZtbEI3Onm3QBw3aA0p5GS_QTdgc8xHIyeNVlOfZmPLc5dsLgU5mQhPekLGopV6ALs1nnsNIWZF_vm3xesBpqCP9_dR8ePy4nb9pbz--vlqvbouJaN1LEFWvOk100r2tKOyxQNT0FJCOZFdjaHtG95RJjUwyvEAA-1V3RLFOW2aXlVHxaedd0n9nC3axjySWLyZwW-EAyP-zVgzip_uQXDW8arFWfB-L_DuPukQxWyC1NMEVrsUBG1J23S5S5bRd_-hdy55m8f7S9UkM12mPuwo6V0IXg_PzRAstnsV272K_V4zfrrDR2MVPJqX6T_iJKRj</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2717516438</pqid></control><display><type>article</type><title>Risk Factors for Chemotherapy-Induced Peripheral Neuropathy Caused by Nanoparticle Albumin-Bound Paclitaxel in Advanced Breast Cancer</title><source>PubMed Central Open Access</source><source>Wiley-Blackwell Open Access Titles</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Guo, Qie ; Zhang, Haonan ; Li, Xiao ; Quan, Xianghua</creator><contributor>De Vita, Alessandro ; Alessandro De Vita</contributor><creatorcontrib>Guo, Qie ; Zhang, Haonan ; Li, Xiao ; Quan, Xianghua ; De Vita, Alessandro ; Alessandro De Vita</creatorcontrib><description>Breast cancer (BC) is one of the most common malignancies affecting women and the leading cause of related mortality worldwide. An estimated 2260000 new cases of BC were diagnosed in 2020, which have seriously threatened the health. Paclitaxel (PTX), a natural product isolated from the bark of the pacific yew, has been found to be effective in treating advanced BC. Chemotherapy-induced peripheral neuropathy (CIPN), which refers to the damage to the peripheral nerves caused by exposure to a neurotoxic chemotherapeutic agent, is a common side effect affecting the patients undergoing PTX chemotherapy. Significant research efforts are needed to identify the various risk factors associated with CIPN. Here, a univariate analysis in BC patients with nanonab-PTX treatment was performed. The rate of CIPN in BC patients with albumin-bound paclitaxel (nab-PTX) for more than four weeks was significantly higher than that of patients with chemotherapy for less than four weeks. Moreover, the rate of CIPN in BC patients receiving nab-PTX first-line chemotherapy was remarkably higher than that in BC patients receiving paclitaxel as a sequence scheme. Taken together, chemotherapy cycles and the priority of nab-PTX-based chemotherapy can be considered the potential risk factors for CIPN induced by nab-PTX.</description><identifier>ISSN: 2314-6133</identifier><identifier>EISSN: 2314-6141</identifier><identifier>DOI: 10.1155/2022/9430952</identifier><language>eng</language><publisher>New York: Hindawi</publisher><subject>Age ; Albumin ; Albumins ; Body mass index ; Breast cancer ; Cancer therapies ; Chemotherapy ; Disease ; Health risks ; Medical prognosis ; Metastasis ; Nanoparticles ; Natural products ; Neurotoxicity ; Paclitaxel ; Patients ; Peripheral nerves ; Peripheral neuropathy ; Quality of life ; Risk analysis ; Risk factors ; Statistical analysis ; Surgery</subject><ispartof>BioMed research international, 2022-09, Vol.2022, p.1-7</ispartof><rights>Copyright © 2022 Qie Guo et al.</rights><rights>Copyright © 2022 Qie Guo et al. This is an open access article distributed under the Creative Commons Attribution License (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. https://creativecommons.org/licenses/by/4.0</rights><rights>Copyright © 2022 Qie Guo et al. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c425t-ac396be4edcb282c70f4da721291c850a7b69824cea4290faf2bd571d99266bd3</citedby><cites>FETCH-LOGICAL-c425t-ac396be4edcb282c70f4da721291c850a7b69824cea4290faf2bd571d99266bd3</cites><orcidid>0000-0002-3206-2236 ; 0000-0002-6572-3205</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489370/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489370/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids></links><search><contributor>De Vita, Alessandro</contributor><contributor>Alessandro De Vita</contributor><creatorcontrib>Guo, Qie</creatorcontrib><creatorcontrib>Zhang, Haonan</creatorcontrib><creatorcontrib>Li, Xiao</creatorcontrib><creatorcontrib>Quan, Xianghua</creatorcontrib><title>Risk Factors for Chemotherapy-Induced Peripheral Neuropathy Caused by Nanoparticle Albumin-Bound Paclitaxel in Advanced Breast Cancer</title><title>BioMed research international</title><description>Breast cancer (BC) is one of the most common malignancies affecting women and the leading cause of related mortality worldwide. An estimated 2260000 new cases of BC were diagnosed in 2020, which have seriously threatened the health. Paclitaxel (PTX), a natural product isolated from the bark of the pacific yew, has been found to be effective in treating advanced BC. Chemotherapy-induced peripheral neuropathy (CIPN), which refers to the damage to the peripheral nerves caused by exposure to a neurotoxic chemotherapeutic agent, is a common side effect affecting the patients undergoing PTX chemotherapy. Significant research efforts are needed to identify the various risk factors associated with CIPN. Here, a univariate analysis in BC patients with nanonab-PTX treatment was performed. The rate of CIPN in BC patients with albumin-bound paclitaxel (nab-PTX) for more than four weeks was significantly higher than that of patients with chemotherapy for less than four weeks. Moreover, the rate of CIPN in BC patients receiving nab-PTX first-line chemotherapy was remarkably higher than that in BC patients receiving paclitaxel as a sequence scheme. Taken together, chemotherapy cycles and the priority of nab-PTX-based chemotherapy can be considered the potential risk factors for CIPN induced by nab-PTX.</description><subject>Age</subject><subject>Albumin</subject><subject>Albumins</subject><subject>Body mass index</subject><subject>Breast cancer</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Disease</subject><subject>Health risks</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Nanoparticles</subject><subject>Natural products</subject><subject>Neurotoxicity</subject><subject>Paclitaxel</subject><subject>Patients</subject><subject>Peripheral nerves</subject><subject>Peripheral neuropathy</subject><subject>Quality of life</subject><subject>Risk analysis</subject><subject>Risk factors</subject><subject>Statistical analysis</subject><subject>Surgery</subject><issn>2314-6133</issn><issn>2314-6141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kc1q3DAQgE1JoSHNLQ8g6KWQupFk-UeXwmZJ2kBIS0nPYizJtVJbcvSTZB-g711tdwm0h-giaeabjxmmKE4I_khIXZ9RTOkZZxXmNX1VHNKKsLIhjBw8v6vqTXEcwh3OpyMN5s1h8fu7Cb_QJcjofECD82g96tnFUXtYNuWVVUlqhb5pb5ZtbEI3Onm3QBw3aA0p5GS_QTdgc8xHIyeNVlOfZmPLc5dsLgU5mQhPekLGopV6ALs1nnsNIWZF_vm3xesBpqCP9_dR8ePy4nb9pbz--vlqvbouJaN1LEFWvOk100r2tKOyxQNT0FJCOZFdjaHtG95RJjUwyvEAA-1V3RLFOW2aXlVHxaedd0n9nC3axjySWLyZwW-EAyP-zVgzip_uQXDW8arFWfB-L_DuPukQxWyC1NMEVrsUBG1J23S5S5bRd_-hdy55m8f7S9UkM12mPuwo6V0IXg_PzRAstnsV272K_V4zfrrDR2MVPJqX6T_iJKRj</recordid><startdate>20220913</startdate><enddate>20220913</enddate><creator>Guo, Qie</creator><creator>Zhang, Haonan</creator><creator>Li, Xiao</creator><creator>Quan, Xianghua</creator><general>Hindawi</general><general>Hindawi Limited</general><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7QO</scope><scope>7T7</scope><scope>7TK</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>CWDGH</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3206-2236</orcidid><orcidid>https://orcid.org/0000-0002-6572-3205</orcidid></search><sort><creationdate>20220913</creationdate><title>Risk Factors for Chemotherapy-Induced Peripheral Neuropathy Caused by Nanoparticle Albumin-Bound Paclitaxel in Advanced Breast Cancer</title><author>Guo, Qie ; Zhang, Haonan ; Li, Xiao ; Quan, Xianghua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c425t-ac396be4edcb282c70f4da721291c850a7b69824cea4290faf2bd571d99266bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Age</topic><topic>Albumin</topic><topic>Albumins</topic><topic>Body mass index</topic><topic>Breast cancer</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Disease</topic><topic>Health risks</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Nanoparticles</topic><topic>Natural products</topic><topic>Neurotoxicity</topic><topic>Paclitaxel</topic><topic>Patients</topic><topic>Peripheral nerves</topic><topic>Peripheral neuropathy</topic><topic>Quality of life</topic><topic>Risk analysis</topic><topic>Risk factors</topic><topic>Statistical analysis</topic><topic>Surgery</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Guo, Qie</creatorcontrib><creatorcontrib>Zhang, Haonan</creatorcontrib><creatorcontrib>Li, Xiao</creatorcontrib><creatorcontrib>Quan, Xianghua</creatorcontrib><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access Journals</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Middle East & Africa Database</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BioMed research international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Guo, Qie</au><au>Zhang, Haonan</au><au>Li, Xiao</au><au>Quan, Xianghua</au><au>De Vita, Alessandro</au><au>Alessandro De Vita</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Risk Factors for Chemotherapy-Induced Peripheral Neuropathy Caused by Nanoparticle Albumin-Bound Paclitaxel in Advanced Breast Cancer</atitle><jtitle>BioMed research international</jtitle><date>2022-09-13</date><risdate>2022</risdate><volume>2022</volume><spage>1</spage><epage>7</epage><pages>1-7</pages><issn>2314-6133</issn><eissn>2314-6141</eissn><abstract>Breast cancer (BC) is one of the most common malignancies affecting women and the leading cause of related mortality worldwide. An estimated 2260000 new cases of BC were diagnosed in 2020, which have seriously threatened the health. Paclitaxel (PTX), a natural product isolated from the bark of the pacific yew, has been found to be effective in treating advanced BC. Chemotherapy-induced peripheral neuropathy (CIPN), which refers to the damage to the peripheral nerves caused by exposure to a neurotoxic chemotherapeutic agent, is a common side effect affecting the patients undergoing PTX chemotherapy. Significant research efforts are needed to identify the various risk factors associated with CIPN. Here, a univariate analysis in BC patients with nanonab-PTX treatment was performed. The rate of CIPN in BC patients with albumin-bound paclitaxel (nab-PTX) for more than four weeks was significantly higher than that of patients with chemotherapy for less than four weeks. Moreover, the rate of CIPN in BC patients receiving nab-PTX first-line chemotherapy was remarkably higher than that in BC patients receiving paclitaxel as a sequence scheme. Taken together, chemotherapy cycles and the priority of nab-PTX-based chemotherapy can be considered the potential risk factors for CIPN induced by nab-PTX.</abstract><cop>New York</cop><pub>Hindawi</pub><doi>10.1155/2022/9430952</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-3206-2236</orcidid><orcidid>https://orcid.org/0000-0002-6572-3205</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2314-6133 |
| ispartof | BioMed research international, 2022-09, Vol.2022, p.1-7 |
| issn | 2314-6133 2314-6141 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9489370 |
| source | PubMed Central Open Access; Wiley-Blackwell Open Access Titles; PubMed Central; Alma/SFX Local Collection |
| subjects | Age Albumin Albumins Body mass index Breast cancer Cancer therapies Chemotherapy Disease Health risks Medical prognosis Metastasis Nanoparticles Natural products Neurotoxicity Paclitaxel Patients Peripheral nerves Peripheral neuropathy Quality of life Risk analysis Risk factors Statistical analysis Surgery |
| title | Risk Factors for Chemotherapy-Induced Peripheral Neuropathy Caused by Nanoparticle Albumin-Bound Paclitaxel in Advanced Breast Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T14%3A52%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Risk%20Factors%20for%20Chemotherapy-Induced%20Peripheral%20Neuropathy%20Caused%20by%20Nanoparticle%20Albumin-Bound%20Paclitaxel%20in%20Advanced%20Breast%20Cancer&rft.jtitle=BioMed%20research%20international&rft.au=Guo,%20Qie&rft.date=2022-09-13&rft.volume=2022&rft.spage=1&rft.epage=7&rft.pages=1-7&rft.issn=2314-6133&rft.eissn=2314-6141&rft_id=info:doi/10.1155/2022/9430952&rft_dat=%3Cproquest_pubme%3E2717516438%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2717516438&rft_id=info:pmid/&rfr_iscdi=true |